<DOC>
	<DOCNO>NCT00556621</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose gemcitabine give together cisplatin radiation therapy see well work treat patient stage II stage III bladder cancer .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Radiation Therapy Treating Patients With Stage II Stage III Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine incidence nature acute late toxicity gemcitabine hydrochloride , cisplatin , concurrent radiotherapy patient stage II III transitional cell carcinoma bladder . ( Phase I ) - Determine efficacy regimen , term local tumor control ( absence local progression ) , patient . ( Phase II ) Secondary - Determine maximum tolerate dose recommended phase II dose gemcitabine hydrochloride administer cisplatin radiotherapy patient . ( Phase I ) - Assess 5- 10-year survival progression-free survival patient treat regimen . ( Phase II ) - Assess quality life patient treat regimen . ( Phase II ) OUTLINE : This phase I , dose-escalation study gemcitabine hydrochloride follow phase II , multicenter study . Patients receive gemcitabine hydrochloride IV 30 minute twice weekly 5 week cisplatin IV continuously 4 day day 2-5 23-26 ( week 1 4 ) . Patients also undergo radiotherapy daily 5 day week 5 week . Three week completion treatment , patient undergo cystoscopy transurethral resection ( TUR ) . Patients residual tumor disease progression undergo radical TUR . After surgery , patient achieve complete response receive gemcitabine hydrochloride IV twice weekly 2 week cisplatin IV continuously 4 day week 1 . Patients also undergo radiotherapy daily 5 day week 2 week . After completion study treatment , patient follow 6-8 week 6 month thereafter .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis muscle invasive transitional cell carcinoma bladder T24a , N0 , M0 ( stage II III disease ) No adenocarcinoma squamous cell carcinoma PATIENT CHARACTERISTICS : WHO performance status ( PS ) 02 Karnofsky PS 70100 % Life expectancy ≥ 6 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Creatinine clearance ≥ 60 mL/min Not pregnant nursing Fertile patient must use effective contraception least 2 month completion study treatment No prior malignancy , except previously treat nonmalignant skin cancer carcinoma situ cervix No prior serious digestive complication ( e.g. , ulcerative colitis complicate diverticulosis ) PRIOR CONCURRENT THERAPY : No prior radiotherapy chemotherapy ( except intravesical instillation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>